Remarkable progress has been made in the development of biomarker-driven targeted
therapies for patients with multiple cancer types, including melanoma, breast and lung …

Colorectal cancer (CRC) is often diagnosed at an advanced stage when tumor cell
dissemination has taken place. Chemo-and targeted therapies provide only a limited …

Colorectal cancer (CRC) is one of the most common malignancies in Western countries.
Over the last 20 years, and the last decade in particular, the clinical outcome for patients with …

The most recent version of the European Society for Medical Oncology (ESMO) consensus
guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was …

The number of molecularly stratified treatment options available to patients with colorectal
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …

Objectives: To develop evidence-based guideline recommendations through a systematic
review of the literature to establish standard molecular biomarker testing of colorectal cancer …

Background Colorectal cancer (CRC) is still a leading cause of cancer-related deaths in the
United States and worldwide, despite recent improvements in cancer management. CRC …

Despite development of novel agents targeting oncogenic pathways, matching targeted
therapies to the genetic status of individual tumors is proving to be a daunting task for …

Circulating tumor DNA (ctDNA) in fluids has gained attention because ctDNA seems to
identify tumor-specific abnormalities, which could be used for diagnosis, follow-up of …

Abstract Background Wild type RAS (RAS-wt) status is predictive of the activities of the anti-
epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab (C) and …